Clinical Trial Detail

NCT ID NCT02783300
Title Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

triple-receptor negative breast cancer

lung non-small cell carcinoma

ureter transitional cell carcinoma

adenoid cystic carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

estrogen-receptor positive breast cancer

Advanced Solid Tumor

non-Hodgkin lymphoma

glioblastoma multiforme

Therapies

GSK3326595

Age Groups: senior adult

No variant requirements are available.